Florian Schuch

Learn More
OBJECTIVE To prospectively analyse the risk for disease relapses in patients with rheumatoid arthritis (RA) in sustained remission, either continuing, tapering or stopping disease-modifying antirheumatic drugs (DMARDs) in a prospective randomised controlled trial. METHODS Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission is a(More)
OBJECTIVE To analyse the role of multibiomarker disease activity (MBDA) score in predicting disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who tapered disease modifying antirheumatic drug (DMARD) therapy in RETRO, a prospective randomised controlled trial. METHODS MBDA scores (scale 1-100) were determined based on 12(More)
OBJECTIVES Recent findings suggest that autoimmune disorders predispose to a diminished capacity to taste and smell. This has been shown for patients with systemic lupus erythematosus as well as for patients with rheumatoid arthritis (RA). Granulomatosis with polyangiitis (GPA), with its particular manifestations in the upper respiratory tract, may(More)
OBJECTIVES To investigate the occurrence and risk factors for infections in RA patients treated with tocilizumab. METHODS A cohort of all RA patients (n = 112) starting tocilizumab therapy between October 2008 and March 2010 in Northern Bavaria was screened for infections. Mild/moderate and severe infections were recorded. Multivariate logistic regression(More)
OBJECTIVE To investigate whether MHC class II expression on myeloid cells of patients with treatment-naive early rheumatoid arthritis (RA) correlates with disease progression. METHODS Monocytes were isolated by negative selection from the peripheral blood of 15 patients with early RA (disease duration < or =12 months), differentiated to macrophages and(More)
Current EULAR guidelines state that biologic DMARD (bDMARD) therapy should be administered in combination with MTX or other conventional synthetic (cs) DMARD in RA. Nonetheless, a third of patients for whom a bDMARD agent is prescribed take it in the absence of concurrent csDMARD therapy. While the reasons underlying the low uptake of bDMARD-csDMARD(More)
PURPOSE To use the Monte Carlo code PENELOPE to study attenuation and tissue equivalence properties of a-Al2O3:C for OSL dosimetry. METHODS Mass attenuation coefficients of α-Al2O3 and α-Al2O3:C with carbon percent weight concentrations from 1% to 150% were simulated with PENELOPE Monte Carlo code and compared to mass attenuation coefficients from soft(More)
DOI 10.1007/s00393-005-0012-5 Online publiziert: 20. Januar 2006 © Springer Medizin Verlag 2006 H.-M. Lorenz6 · K. Minden1 · F. Schuch2 · S. Hofmann3 · J. Grifka4 · C. Fiehn5 1 Kinderklinik, HELIOS Klinikum, Berlin 2 Rheumatologische Schwerpunktpraxis, Erlangen 3 Deutsche Rheuma-Liga e.V., Landesverband Baden-Württemberg, Bruchsal 4 Klinik und Poliklinik(More)
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment Juergen Rech, Axel J Hueber, Stephanie Finzel, Matthias Englbrecht, Judith Haschka, Bernhard Manger, Arnd Kleyer, Michaela Reiser, Jayme Fogagnolo Cobra, Camille Figueiredo, Hans-Peter Tony, Stefan(More)
Die Radiosynoviorthese (RSO) ist eine lokale, intraartikuläre Strahlentherapie, bei der, je nach Gelenkgröße, bestimmte Betastrahler (Erbium-169, Rhenium-186 und Yttrium-90) in das betroffene Gelenk injiziert werden. Die RSO ist eine etablierte Behandlungsmethode bei rheumatischen Gelenkerkrankungen oder entzündlichen Begleitreaktionen (Synovialitis) bei(More)